Qiagen expands QIAcuity gene expression tools, shares remain muted on NYSE

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-28, 11:31.

Qiagen N.V. (NL0012169213) has expanded its QIAcuity digital PCR ecosystem with new gene expression tools aimed at broader laboratory adoption. The company, whose shares trade on the NYSE under the ticker QGEN, sees the additions as a way to deepen its diagnostics and life-science footprint, according to Zacks.

What Zacks reports on Qiagen

Zacks reported that Qiagen recently added new gene expression solutions, enhanced multiplexing capabilities, workflow automation and standardized analysis tools to the QIAcuity dPCR platform, targeting more robust use across research and clinical settings. Zacks analysis on the QIAcuity expansion The report notes that QIAcuity is positioned for precise quantification of nucleic acids in gene expression and other applications, reflecting Qiagen’s push into high-growth segments of molecular testing.

Zacks also highlights that Qiagen currently carries a Zacks Rank #4 (Sell), pointing to cautious analyst sentiment despite the operational expansion in digital PCR tools. Zacks rank and quote page for QGEN In addition, the research house underscores that the company’s broader diagnostics portfolio competes with other molecular players in North America and Europe, where NYSE listing supports visibility among US investors.

Year-to-date performance and sector context

According to Zacks, Qiagen shares have traded flat immediately after the QIAcuity news, suggesting a muted short-term reaction to the product expansion. Zacks commentary on share response Over the year-to-date period, however, QGEN shares are down 21.7 percent, compared with a roughly 1.3 percent decline for the broader medical instruments and supplies industry tracked by Zacks.

MarketBeat data show that Qiagen closed at 39.36 US dollars on the NYSE on 2026-06-26, up 1.07 percent on the day, with extended trading indicating 39.00 dollars as of the same evening. MarketBeat quote and trading data for QGEN The listing sits in the biomedical and gene sector on the NYSE, giving investors a liquid proxy on molecular diagnostics alongside peers in the MED - BIOMED/GENE sub-industry.

The product behind the stock

Qiagen’s QIAcuity platform is a digital PCR system designed for high-precision quantification of DNA and RNA, including gene expression analysis, mutation detection and copy number variation. The recent expansion adds gene expression assays and workflow tools to support labs in oncology, infectious disease and translational research.

Where the Qiagen shares trade today

Qiagen shares (NL0012169213) last traded on the NYSE at 39.36 US dollars as of 2026-06-26, 15:59 Eastern Time, with an after-hours indication at 39.00 dollars on the same date.

Disclaimer: This article is for informational purposes only and does not contain investment advice, recommendations or solicitations to buy or sell securities.